Comparative Pharmacology
Head-to-head clinical analysis: CUROSURF versus SURVANTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CUROSURF versus SURVANTA.
CUROSURF vs SURVANTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CUROSURF is a natural porcine lung surfactant containing phospholipids and surfactant-associated proteins B and C. It reduces surface tension in the alveoli, preventing alveolar collapse at end-expiration and improving lung compliance and gas exchange.
Survanta is a natural bovine lung extract containing phospholipids, neutral lipids, and surfactant-associated proteins. It reduces surface tension in the alveoli, preventing alveolar collapse at end-expiration and improving lung compliance.
Curosurf is administered intratracheally as a single dose of 100-200 mg/kg (1.25-2.5 mL/kg) of birth weight, given as soon as possible after birth. Repeat doses of 100 mg/kg (1.25 mL/kg) may be given at 12-hour intervals up to a total of 3 doses if needed.
100 mg phospholipids/kg (4 mL/kg) intratracheally, administered as 4 divided aliquots, repeated every 6 hours up to 4 doses as needed.
None Documented
None Documented
The terminal elimination half-life is approximately 24-48 hours in preterm infants, reflecting slow clearance from the lungs; clinical effects on lung function can be seen within minutes.
terminal elimination half-life of approximately 67 hours (range 37-85 hours) due to slow clearance from lungs; clinically, effects persist for days after single dose
The primary route of elimination is via alveolar macrophages and clearance from the lungs; renal and biliary excretion are negligible as the drug is a surfactant administered directly to the lungs.
primarily pulmonary uptake and catabolism; minimal renal or biliary excretion; elimination via alveolar macrophages and recycling in surfactant
Category C
Category C
Pulmonary Surfactant
Pulmonary Surfactant